



IA4R-01PCT/PTO 30 DEC 2005

PCT

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74854

Yoshinori SEKIGUCHI, *et al.*

Appln. No.: 10/551,431

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: September 30, 2005

For: NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT
RELATED TO THE USE THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Susan J. Mack
Registration No. 30,951

Date: December 30, 2005



Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,431
Confirmation Number	Not Yet Assigned
Filing Date	September 28, 2005
First Named Inventor	Yoshinori SEKIGUCHI
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q74854

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	92/07844	A1	05-14-1992	Pfizer Inc.	
		WO	03/070244	A1	08-28-2003	Abbott Laboratories	
		WO	03/105850	A1	12-24-2003	Abbott Laboratories	
		WO	03/045313	A2	06-05-2003	Merck & Co., Inc.	
		WO	03/045920	A1	06-05-2003	Merck & Co., Inc.	
		WO	2004/004726	A1	01-15-2004	Astrazeneca UK Limited	
		WO	01/72710	A1	10-04-2001	Nippon Shinyaku Co., Ltd.	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		A. PAUL KRAPCHO, <i>et al.</i> , "Mono-Protected Diamines. N-tert-Butoxycarbonyl- α,ω -Alkanediamines from α,ω -Alkanediamines," <i>Synthetic Communications</i> , 20(16), 2559-2564, 1990.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

~~JC09 Rec'd PCT/PTD~~
~~Completely Answered~~

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

Confirmation Number

Filing Date

First Named Inventor

Art Unit

Examiner Name

Attorney Docket Number

U.S. National Stage Entry of
PCT/JP2004/004554
-filed March 30, 2004

Not Yet Assigned

September 30, 2005

Yoshinori SEKIGUCHI

Not Yet Assigned

Not Yet Assigned

Q74854

Sheet

1

of

1

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		D. GIARDINA, <i>et al.</i> , "Structure-Activity Relationships in Prazosin-Related Compounds. 2. Role of the Piperazine Ring on α -Blocking Activity," <i>Journal of Medicinal Chemistry</i> , 1993, 36(6), pages 690-8	
		E.F. ELSLAGER, <i>et al.</i> , "Synthesis and Antimalarial Effects of N2-aryl-N4-[(dialkylamino) alkyl] - and 4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines," <i>Journal of Medicinal Chemistry</i> , 1981, 24(2), pages 127-40	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.